Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Zeon Corporation Reaches An Agreement to Acquire Aurora Microplates

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Zeon Corporation, a world leader in specialty elastomers, polymers, and specialty chemicals, has reached agreement to acquire Aurora Microplates, a leading manufacturer and supplier of high-performance microplates. The official announcement was made in Tokyo today.  The acquisition is expected to be completed by February 28, 2022.

“We are very excited to enter the high-value high-performance microplate market. For more than 20 years we have supplied Aurora Microplates with polymer and film material for its microplates, and we are pleased to be able to enter the drug discovery research markets with a highly respected and knowledgeable partner” said Kimiaki Tanaka, President, and CEO at Zeon Corporation.

The Aurora Microplates business fits into Zeon Corporation’s strategy to deliver the best material and products to enable users involved in research and diagnostics to improve human health. Through Aurora Microplates, Zeon will support front-line scientists in their quest to better understand the subtle clues involved in animal and human health.

“We are thrilled to be working in complete synergy with Zeon, our resin and film supplier since Aurora was born more than 20 years ago” said Charles Powell, Managing Partner at Aurora Microplates, “this combination of raw material supplier and Microplate Manufacturer is unique in the marketplace- and will provide our current and future microplates users piece of mind with respect to microplate supply for their critical research needs.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine